Pregled bibliografske jedinice broj: 732791
Efficacy of oraly applied probiotic capsules for bacterial vaginosis and other vaginal infection:a double blind, randomised, placebo-controled study
Efficacy of oraly applied probiotic capsules for bacterial vaginosis and other vaginal infection:a double blind, randomised, placebo-controled study // European journal of obstetrics, gynecology, and reproductive biology, 168 (2013), 1; 75-79 doi:10.1016/j.ejogrb.2012.12.031 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 732791 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Efficacy of oraly applied probiotic capsules for bacterial vaginosis and other vaginal infection:a double blind, randomised, placebo-controled study
Autori
Vujić, Goran ; Jajac Knez, Alenka ; Despot Stefanović, Vedrana ; Kuzmić Vrbanović, Vedrana
Izvornik
European journal of obstetrics, gynecology, and reproductive biology (0301-2115) 168
(2013), 1;
75-79
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
bacterial vaginosis; oral probiotics; placebo-controlled study
Sažetak
To assess the efficacy of orally administered capsules containing the probiotics Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (Lactogyn, JGL, Rijeka, Croatia) compared to placebo in otherwise healthy women diagnosed with bacterial vaginosis. Randomized, double-blind, multicentric, placebo-controlled trial, including a total of 544 subjects. Included were women older than 18 years of age, diagnosed with vaginal infection. Subjects received either probiotic (395 subjects or 72.6%) or identical-looking placebo capsules (149 subjects or 27.4%, ) per day over a period of 6 weeks. Six and 12 weeks after the beginning of the study, subjects underwent two additional gynecological examinations and their vaginal swabs were evaluated by a clinical cytologist. Mean follow-up period after the baseline visit was 44 days. After this period, restitution to balanced vaginal microbiota was reported in 40 subjects (26.9%) in the placebo group, compared to 243 subjects (61.5%) in the probiotic group. Differences between groups were statistically significant at p < 0.001. After the additional 6 weeks of follow up, normal vaginal microbiota were still present in more than half (51.1%) of subjects in the probiotic group, but only in around one-fifth (20.8%) of subjects who were taking placebo (p < 0.001). Oral probiotics could be an alternative, side effect-free treatment for one of the most common indications in gynecology, combining the good aspects of both metronidazole and vaginal capsules.
Izvorni jezik
Hrvatski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE